CG Oncology (NASDAQ:CGON) is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder ...

Patients with early-stage bladder cancer are often able to maintain their usual routines. Some may experience urinary ...

The approval relies on positive data from the POTOMAC Phase III trial.

Stock Moves Higher Following Patent AnnouncementShares of ImmunityBio (NASDAQ:IBRX) gained 4. 5% in premarket trading on ...

The principal investigator of the study leading to approval said this new immunotherapy could be a "game changer" in bladder cancer. FDA last night approved nogapendekin alfa inbakicept-pmln (NAI) ...

Combination significantly improved disease-free survival in phase III trial ...

Male doctor explaining senior couple over laptop. Elderly man and woman are listening to medical expertise. They are sitting at desk in hospital. After the BCG shortage began, patients with non-muscle ...

Tecentriq combined with BCG did not enhance outcomes for high-risk NMIBC patients compared to BCG alone, with similar event-free survival rates. The ALBAN trial reported higher rates of side effects ...

Bacillus Calmette-Guérin (BCG) vaccine is the live attenuated vaccine form of Mycobacterium bovis used to prevent tuberculosis and other mycobacterial infections. Now, using zebrafish “avatars,” a ...

AstraZeneca’s IMFINZI ® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve ...

For people with non–muscle invasive bladder cancer (NMIBC), the reality can be especially pronounced. The disease is often persistent, requiring repeated treatments, frequent monitoring, and ongoing ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...